Other research analysts have also recently issued reports about the stock. TheStreet cut shares of USANA Health Sciences from a “b” rating to a “c+” rating in a research report on Wednesday, February 9th. Zacks Investment Research upgraded shares of USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 13th. Finally, DA Davidson assumed coverage on shares of USANA Health Sciences in a research report on Wednesday, April 13th. They issued a “neutral” rating and a $86.00 target price for the company. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $108.33.
Shares of NYSE USNA traded down $3.22 during mid-day trading on Tuesday, reaching $75.52. The company had a trading volume of 69,800 shares, compared to its average volume of 70,238. The firm has a 50 day simple moving average of $82.41 and a two-hundred day simple moving average of $93.07. The stock has a market cap of $1.45 billion, a P/E ratio of 13.23 and a beta of 0.87. USANA Health Sciences has a 52-week low of $75.52 and a 52-week high of $107.85.
In other news, Director Gilbert A. Fuller sold 312 shares of the company’s stock in a transaction on Tuesday, February 15th. The stock was sold at an average price of $89.62, for a total transaction of $27,961.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joshua Foukas sold 3,303 shares of the company’s stock in a transaction on Wednesday, March 2nd. The stock was sold at an average price of $89.93, for a total value of $297,038.79. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,653 shares of company stock valued at $600,825. 0.36% of the stock is currently owned by corporate insiders.
Hedge funds have recently bought and sold shares of the company. Crew Capital Management Ltd. bought a new stake in USANA Health Sciences during the fourth quarter worth $202,000. UBS Asset Management Americas Inc. grew its position in USANA Health Sciences by 29.4% during the third quarter. UBS Asset Management Americas Inc. now owns 13,284 shares of the company’s stock worth $1,225,000 after buying an additional 3,017 shares in the last quarter. Cubist Systematic Strategies LLC grew its position in USANA Health Sciences by 83.0% during the third quarter. Cubist Systematic Strategies LLC now owns 5,664 shares of the company’s stock worth $522,000 after buying an additional 2,569 shares in the last quarter. Blue Bell Private Wealth Management LLC purchased a new position in USANA Health Sciences during the fourth quarter worth about $101,000. Finally, Martingale Asset Management L P grew its position in USANA Health Sciences by 141.0% during the third quarter. Martingale Asset Management L P now owns 12,785 shares of the company’s stock worth $1,179,000 after buying an additional 7,480 shares in the last quarter. Institutional investors own 54.82% of the company’s stock.
USANA Health Sciences Company Profile (Get Rating)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.
- Get a free copy of the StockNews.com research report on USANA Health Sciences (USNA)
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- The Sherwin-Williams Company Bottoms Above Institutional Support
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
- Whirlpool Is A Steal At These Prices
- Kimberly-Clark Pops On Successful Price Pass-Through
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.